文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基因组分析揭示 HDAC1 调控胰腺癌中具有临床相关性的转录程序。

Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer.

机构信息

The University of Alabama in Huntsville, Huntsville, AL, 35899, USA.

HudsonAlpha Institute for Biotechnology, 601 Genome Way, Huntsville, AL, 35806, USA.

出版信息

BMC Cancer. 2023 Nov 23;23(1):1137. doi: 10.1186/s12885-023-11645-0.


DOI:10.1186/s12885-023-11645-0
PMID:37996815
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10666341/
Abstract

Novel strategies are needed to combat multidrug resistance in pancreatic ductal adenocarcinoma (PDAC). We applied genomic approaches to understand mechanisms of resistance in order to better inform treatment and precision medicine. Altered function of chromatin remodeling complexes contribute to chemoresistance. Our study generates and analyzes genomic and biochemical data from PDAC cells overexpressing HDAC1, a histone deacetylase involved in several chromatin remodeling complexes. We characterized the impact of overexpression on drug response, gene expression, HDAC1 binding, and chromatin structure using RNA-sequencing and ChIP-sequencing for HDAC1 and H3K27 acetylation. Integrative genomic analysis shows that HDAC1 overexpression promotes activation of key resistance pathways including epithelial to mesenchymal transition, cell cycle, and apoptosis through global chromatin remodeling. Target genes are similarly altered in patient tissues and show correlation with patient survival. We also demonstrate that direct targets of HDAC1 that also show altered chromatin are enriched near genes associated with altered GTPase activity. HDAC1 target genes identified using in vitro methods and observed in patient tissues were used to develop a clinically relevant nine-transcript signature associated with patient prognosis. Integration of multiple genomic and biochemical data types enables understanding of multidrug resistance and tumorigenesis in PDAC, a disease in desperate need of novel treatment strategies.

摘要

需要新的策略来对抗胰腺导管腺癌 (PDAC) 的多药耐药性。我们应用基因组方法来了解耐药机制,以便更好地为治疗和精准医学提供信息。染色质重塑复合物功能改变导致化疗耐药。我们的研究生成并分析了过表达组蛋白去乙酰化酶 1 (HDAC1) 的 PDAC 细胞的基因组和生化数据,HDAC1 参与多个染色质重塑复合物。我们使用 RNA 测序和 HDAC1 和 H3K27 乙酰化的 ChIP-seq 来研究过表达对药物反应、基因表达、HDAC1 结合和染色质结构的影响。综合基因组分析表明,HDAC1 过表达通过全局染色质重塑促进关键耐药途径的激活,包括上皮间质转化、细胞周期和细胞凋亡。靶基因在患者组织中也发生类似改变,并与患者生存相关。我们还证明,HDAC1 的直接靶基因也显示出染色质改变,这些基因在靠近与 GTPase 活性改变相关的基因附近富集。使用体外方法鉴定的 HDAC1 靶基因并在患者组织中观察到的靶基因用于开发与患者预后相关的具有临床相关性的九转录本特征。整合多种基因组和生化数据类型可理解 PDAC 中的多药耐药性和肿瘤发生,这种疾病急需新的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/636729ded753/12885_2023_11645_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/a7e06fa839c4/12885_2023_11645_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/90b1f87c64fb/12885_2023_11645_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/3061af0be2a5/12885_2023_11645_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/63c9a1fe1977/12885_2023_11645_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/d4f27f52ad86/12885_2023_11645_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/636729ded753/12885_2023_11645_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/a7e06fa839c4/12885_2023_11645_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/90b1f87c64fb/12885_2023_11645_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/3061af0be2a5/12885_2023_11645_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/63c9a1fe1977/12885_2023_11645_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/d4f27f52ad86/12885_2023_11645_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a7a/10666341/636729ded753/12885_2023_11645_Fig6_HTML.jpg

相似文献

[1]
Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer.

BMC Cancer. 2023-11-23

[2]
Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.

BMC Cancer. 2021-5-29

[3]
Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer.

Cancer Sci. 2018-7-23

[4]
Histone Deacetylase 1 (HDAC1) Negatively Regulates Thermogenic Program in Brown Adipocytes via Coordinated Regulation of Histone H3 Lysine 27 (H3K27) Deacetylation and Methylation.

J Biol Chem. 2016-2-26

[5]
Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.

BMC Cancer. 2023-6-8

[6]
Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.

Pancreas. 2010-10

[7]
MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity.

Cell Death Dis. 2019-2-27

[8]
A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma.

J Exp Clin Cancer Res. 2020-9-7

[9]
Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer.

Cancer Biol Ther. 2011-4-1

[10]
Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice.

Blood. 2013-1-3

引用本文的文献

[1]
Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy.

Int J Mol Sci. 2025-1-9

[2]
The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications.

Front Immunol. 2024-11-15

[3]
Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma.

Front Immunol. 2024

本文引用的文献

[1]
Translational advances in pancreatic ductal adenocarcinoma therapy.

Nat Cancer. 2022-3

[2]
TMEM43 promotes pancreatic cancer progression by stabilizing PRPF3 and regulating RAP2B/ERK axis.

Cell Mol Biol Lett. 2022-3-8

[3]
Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance.

Cancers (Basel). 2021-11-4

[4]
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress.

Cancers (Basel). 2021-9-2

[5]
Characterization of Histone Deacetylase Mechanisms in Cancer Development.

Front Oncol. 2021-7-29

[6]
The biological underpinnings of therapeutic resistance in pancreatic cancer.

Genes Dev. 2021-7-1

[7]
The Crossroads between RAS and RHO Signaling Pathways in Cellular Transformation, Motility and Contraction.

Genes (Basel). 2021-5-27

[8]
Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.

BMC Cancer. 2021-5-29

[9]
Ral GTPase-activating protein regulates the malignancy of pancreatic ductal adenocarcinoma.

Cancer Sci. 2021-8

[10]
Recent developments of HDAC inhibitors: Emerging indications and novel molecules.

Br J Clin Pharmacol. 2021-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索